Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16027488 | 1.00 | TYR (0.48) | TYRCYP1A2NFKB1THPOALDH1A1 | |
| SCHEMBL1660999 | 0.91 | TYR (0.60) | TYR | |
| SCHEMBL1661003 | 0.91 | TYR (0.60) | TYR | |
| SCHEMBL14120256 | 0.91 | TYR (0.60) | TYR | |
| SCHEMBL16076778 | 0.88 | TYR (0.45) | TYR | |
| SCHEMBL20056565 | 0.82 | HK1 (0.46) | TYR | |
| SCHEMBL2035140 | 0.82 | TYR (0.64) | TYR | |
| SCHEMBL2035138 | 0.82 | TYR (0.64) | TYR | |
| SCHEMBL12476682 | 0.81 | TYR (0.56) | TYR | |
| SCHEMBL14120235 | 0.81 | TYR (0.56) | TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970353-B1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMA (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9890176-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2970353-A2 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014165107-A2 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140274930-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274930-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | TLR5, TLR1, MANBA | TYR 735/4885CYP1A2 3033/4885NFKB1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.